157 related articles for article (PubMed ID: 22747980)
1. Validating intramyocardial bone marrow stem cell therapy in combination with coronary artery bypass grafting, the PERFECT Phase III randomized multicenter trial: study protocol for a randomized controlled trial.
Donndorf P; Kaminski A; Tiedemann G; Kundt G; Steinhoff G
Trials; 2012 Jul; 13():99. PubMed ID: 22747980
[TBL] [Abstract][Full Text] [Related]
2. Effect of direct intramyocardial autologous stem cell grafting in the sub-acute phase after myocardial infarction.
Laguna G; DI Stefano S; Maroto L; Fulquet E; Echevarría JR; Revilla A; Urueña N; Sevilla T; Arnold R; Ramos B; Gutiérrez H; Serrador A; San Román JA
J Cardiovasc Surg (Torino); 2018 Apr; 59(2):259-267. PubMed ID: 29582623
[TBL] [Abstract][Full Text] [Related]
3. Autologous CD133+ bone marrow cells and bypass grafting for regeneration of ischaemic myocardium: the Cardio133 trial.
Nasseri BA; Ebell W; Dandel M; Kukucka M; Gebker R; Doltra A; Knosalla C; Choi YH; Hetzer R; Stamm C
Eur Heart J; 2014 May; 35(19):1263-74. PubMed ID: 24497345
[TBL] [Abstract][Full Text] [Related]
4. Intramyocardial bone marrow stem cell transplantation during coronary artery bypass surgery: a meta-analysis.
Donndorf P; Kundt G; Kaminski A; Yerebakan C; Liebold A; Steinhoff G; Glass A
J Thorac Cardiovasc Surg; 2011 Oct; 142(4):911-20. PubMed ID: 21376346
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of direct Cardiac Shockwave Therapy in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting (the CAST-HF trial): study protocol for a randomized controlled trial.
Pölzl L; Nägele F; Graber M; Hirsch J; Lobenwein D; Mitrovic M; Mayr A; Theurl M; Schreinlechner M; Pamminger M; Dorfmüller C; Grimm M; Gollmann-Tepeköylü C; Holfeld J
Trials; 2020 May; 21(1):447. PubMed ID: 32473644
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic stem-cell senescence and myocardial repair - Coronary artery disease genotype/phenotype analysis of post-MI myocardial regeneration response induced by CABG/CD133+ bone marrow hematopoietic stem cell treatment in RCT PERFECT Phase 3.
Wolfien M; Klatt D; Salybekov AA; Ii M; Komatsu-Horii M; Gaebel R; Philippou-Massier J; Schrinner E; Akimaru H; Akimaru E; David R; Garbade J; Gummert J; Haverich A; Hennig H; Iwasaki H; Kaminski A; Kawamoto A; Klopsch C; Kowallick JT; Krebs S; Nesteruk J; Reichenspurner H; Ritter C; Stamm C; Tani-Yokoyama A; Blum H; Wolkenhauer O; Schambach A; Asahara T; Steinhoff G
EBioMedicine; 2020 Jul; 57():102862. PubMed ID: 32629392
[TBL] [Abstract][Full Text] [Related]
7. The IMPACT-CABG trial: A multicenter, randomized clinical trial of CD133
Noiseux N; Mansour S; Weisel R; Stevens LM; Der Sarkissian S; Tsang K; Crean AM; Larose E; Li SH; Wintersperger B; Vu MQ; Prieto I; Li RK; Roy DC; Yau TM
J Thorac Cardiovasc Surg; 2016 Dec; 152(6):1582-1588.e2. PubMed ID: 27665225
[TBL] [Abstract][Full Text] [Related]
8. COMPARE-AMI trial: comparison of intracoronary injection of CD133+ bone marrow stem cells to placebo in patients after acute myocardial infarction and left ventricular dysfunction: study rationale and design.
Mansour S; Roy DC; Bouchard V; Nguyen BK; Stevens LM; Gobeil F; Rivard A; Leclerc G; Reeves F; Noiseux N
J Cardiovasc Transl Res; 2010 Apr; 3(2):153-9. PubMed ID: 20560029
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of direct cardiac shockwave therapy in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting (the CAST-HF trial): study protocol for a randomized controlled trial-an update.
Nägele F; Pölzl L; Graber M; Hirsch J; Mayr A; Pamminger M; Troger F; Theurl M; Schreinlechner M; Sappler N; Dorfmüller C; Mitrovic M; Ulmer H; Grimm M; Gollmann-Tepeköylü C; Holfeld J
Trials; 2022 Dec; 23(1):988. PubMed ID: 36494706
[TBL] [Abstract][Full Text] [Related]
10. Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial.
Karantalis V; DiFede DL; Gerstenblith G; Pham S; Symes J; Zambrano JP; Fishman J; Pattany P; McNiece I; Conte J; Schulman S; Wu K; Shah A; Breton E; Davis-Sproul J; Schwarz R; Feigenbaum G; Mushtaq M; Suncion VY; Lardo AC; Borrello I; Mendizabal A; Karas TZ; Byrnes J; Lowery M; Heldman AW; Hare JM
Circ Res; 2014 Apr; 114(8):1302-10. PubMed ID: 24565698
[TBL] [Abstract][Full Text] [Related]
11. Combined transepicardial and transseptal implantation of autologous CD 133+ bone marrow cells during bypass grafting improves cardiac function in patients with low ejection fraction.
Soetisna TW; Sukmawan R; Setianto B; Mansyur M; Murni TW; Listiyaningsih E; Santoso A
J Card Surg; 2020 Apr; 35(4):740-746. PubMed ID: 32048356
[TBL] [Abstract][Full Text] [Related]
12. Human Umbilical Cord Mesenchymal Stromal Cell Transplantation in Myocardial Ischemia (HUC-HEART Trial). A Study Protocol of a Phase 1/2, Controlled and Randomized Trial in Combination with Coronary Artery Bypass Grafting.
Can A; Ulus AT; Cinar O; Topal Celikkan F; Simsek E; Akyol M; Canpolat U; Erturk M; Kara F; Ilhan O
Stem Cell Rev Rep; 2015 Oct; 11(5):752-60. PubMed ID: 26123356
[TBL] [Abstract][Full Text] [Related]
13. Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies.
Stamm C; Kleine HD; Choi YH; Dunkelmann S; Lauffs JA; Lorenzen B; David A; Liebold A; Nienaber C; Zurakowski D; Freund M; Steinhoff G
J Thorac Cardiovasc Surg; 2007 Mar; 133(3):717-25. PubMed ID: 17320570
[TBL] [Abstract][Full Text] [Related]
14. Impact of preoperative left ventricular function and time from infarction on the long-term benefits after intramyocardial CD133(+) bone marrow stem cell transplant.
Yerebakan C; Kaminski A; Westphal B; Donndorf P; Glass A; Liebold A; Stamm C; Steinhoff G
J Thorac Cardiovasc Surg; 2011 Dec; 142(6):1530-9.e3. PubMed ID: 21664627
[TBL] [Abstract][Full Text] [Related]
15. Implantation of CD133+ stem cells in patients undergoing coronary bypass surgery: IMPACT-CABG pilot trial.
Forcillo J; Stevens LM; Mansour S; Prieto I; Salem R; Baron C; Roy DC; Larose E; Masckauchan D; Noiseux N
Can J Cardiol; 2013 Apr; 29(4):441-7. PubMed ID: 23265095
[TBL] [Abstract][Full Text] [Related]
16. Impact of remote ischemic preconditioning preceding coronary artery bypass grafting on inducing neuroprotection (RIPCAGE): study protocol for a randomized controlled trial.
Gasparovic H; Kopjar T; Rados M; Anticevic A; Rados M; Malojcic B; Ivancan V; Fabijanic T; Cikes M; Milicic D; Gasparovic V; Biocina B
Trials; 2014 Oct; 15():414. PubMed ID: 25348157
[TBL] [Abstract][Full Text] [Related]
17. Early increase in myocardial perfusion after stem cell therapy in patients undergoing incomplete coronary artery bypass surgery.
Gowdak LH; Schettert IT; Rochitte CE; Lisboa LA; Dallan LA; César LA; de Oliveira SA; Krieger JE
J Cardiovasc Transl Res; 2011 Feb; 4(1):106-13. PubMed ID: 21061106
[TBL] [Abstract][Full Text] [Related]
18. A pilot trial of autologous bone marrow mononuclear cell transplantation through grafting artery: a sub-study focused on segmental left ventricular function recovery and scar reduction.
Lu M; Liu S; Zheng Z; Yin G; Song L; Chen H; Chen X; Chen Q; Jiang S; Tian L; He Z; Hu S; Zhao S
Int J Cardiol; 2013 Oct; 168(3):2221-7. PubMed ID: 23478196
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial).
Mathiasen AB; Jørgensen E; Qayyum AA; Haack-Sørensen M; Ekblond A; Kastrup J
Am Heart J; 2012 Sep; 164(3):285-91. PubMed ID: 22980293
[TBL] [Abstract][Full Text] [Related]
20. LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.
Traverse JH; Henry TD; Vaughan DE; Ellis SG; Pepine CJ; Willerson JT; Zhao DX; Simpson LM; Penn MS; Byrne BJ; Perin EC; Gee AP; Hatzopoulos AK; McKenna DH; Forder JR; Taylor DA; Cogle CR; Baraniuk S; Olson RE; Jorgenson BC; Sayre SL; Vojvodic RW; Gordon DJ; Skarlatos SI; Moyè LA; Simari RD;
Tex Heart Inst J; 2010; 37(4):412-20. PubMed ID: 20844613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
